Ionis Pharmaceuticals (MIL:1IONS) Accounts Payable: €41.4 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MIL:1IONS Ionis Pharmaceuticals Inc MIL:1IONS
48 GF Score
Price €48.44
GF Value €44.73
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Ionis Pharmaceuticals Accounts Payable?

Ionis Pharmaceuticals MIL:1IONS 48 Accounts Payable is €41.4 Mil as of Jun. 2026. GuruFocus rates MIL:1IONS with a GF Score™ of 48/100 and a GF Value™ of €44.73 (Modestly Overvalued). The stock has 5 warning signs investors should review.

Ionis Pharmaceuticals's Accounts Payable for the quarter that ended in Jun. 2026 was €41.4 Mil.

Ionis Pharmaceuticals's quarterly Accounts Payable declined from Dec. 2025 (€24.0 Mil) to Mar. 2026 (€22.5 Mil) but then increased from Mar. 2026 (€22.5 Mil) to Jun. 2026 (€41.4 Mil).

Ionis Pharmaceuticals's annual Accounts Payable increased from Dec. 2023 (€23.9 Mil) to Dec. 2024 (€41.0 Mil) but then declined from Dec. 2024 (€41.0 Mil) to Dec. 2025 (€24.0 Mil).

Ionis Pharmaceuticals Accounts Payable Related Terms

Ionis Pharmaceuticals Accounts Payable Historical Data

* Premium members only.

The historical data trend for Ionis Pharmaceuticals's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ionis Pharmaceuticals Accounts Payable Chart

Ionis Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.54 16.92 23.87 41.03 23.98

Ionis Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.77 12.21 23.98 22.52 41.41
MIL:1IONS
48GF Score
Ionis Pharmaceuticals Inc MIL:1IONS
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ionis Pharmaceuticals Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of €41.4 Mil mean?
Ionis Pharmaceuticals (MIL:1IONS) has a Accounts Payable of €41.4 Mil as of Jun. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Ionis Pharmaceuticals and its competitors.
Is Ionis Pharmaceuticals' Accounts Payable too high?
Ionis Pharmaceuticals' current Accounts Payable is €41.4 Mil. Overall, Ionis Pharmaceuticals has a GF Score™ of 48/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ionis Pharmaceuticals' Accounts Payable compare to KYMR and PRAX?
Ionis Pharmaceuticals' Accounts Payable of €41.4 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Ionis Pharmaceuticals and its competitors. Ionis Pharmaceuticals's current Accounts Payable is €41.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ionis Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Ionis Pharmaceuticals (MIL:1IONS) is currently considered Modestly Overvalued. The stock's GF Value™ is €44.73, compared to a current price of €48.44 — trading 8.3% above its estimated fair value. The current Accounts Payable is €41.4 Mil. Ionis Pharmaceuticals' overall GF Score™ is 48/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Ionis Pharmaceuticals (MIL:1IONS), the current Accounts Payable is €41.4 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ionis Pharmaceuticals (MIL:1IONS) Overvalued in 2026?

Based on GuruFocus' analysis, Ionis Pharmaceuticals stock appears to be overvalued. The current stock price of €48.44 is trading 8.3% above its estimated GF Value™ of €44.73. GuruFocus considers Ionis Pharmaceuticals to be Modestly Overvalued.

Key valuation signals for MIL:1IONS:

  • Accounts Payable: €41.4 Mil
  • GF Value™: €44.73 vs. price of €48.44 (8.3% above fair value)
  • GF Score™: 48/100 with 5 warning signs

No single metric tells the full story. See the MIL:1IONS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ionis Pharmaceuticals Business Description

Other Exchanges IONS:USA0JDI:UKISI:Germany
Address 2855 Gazelle Court, Carlsbad, CA, USA, 92010
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
48GF Score

Get the complete analysis for MIL:1IONS

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€48.44
Price
€44.73
GF Value